PLA2G7 and metabolic dysfunction-associated steatotic liver disease: The expression of Lp-PLA2, an indicator related to cardiovascular risk, was significantly decreased in the non-obese group (Figure 2j), referring to that weight loss can significantly improve the risk of cardiovascular atherosclerosis in T2DM patients with NAFLD.